LifeMD, Inc. (NASDAQ:LFMD – Get Free Report) CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $7.55, for a total value of $377,500.00. Following the completion of the transaction, the chief executive officer now directly owns 2,653,715 shares of the company’s stock, valued at approximately $20,035,548.25. This trade represents a 1.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Justin Schreiber also recently made the following trade(s):
- On Thursday, January 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $5.19, for a total value of $129,750.00.
- On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.
LifeMD Trading Down 27.4 %
Shares of NASDAQ:LFMD opened at $5.46 on Monday. The stock has a 50 day moving average of $5.69 and a 200 day moving average of $5.40. The company has a market cap of $236.47 million, a PE ratio of -8.53 and a beta of 1.50. LifeMD, Inc. has a 12-month low of $3.99 and a 12-month high of $12.88.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. Mizuho assumed coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price target for the company. Lake Street Capital assumed coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of LifeMD in a research report on Monday, November 11th. Finally, KeyCorp reduced their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, LifeMD presently has an average rating of “Moderate Buy” and an average target price of $11.14.
Get Our Latest Stock Analysis on LFMD
About LifeMD
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Read More
- Five stocks we like better than LifeMD
- Options Trading – Understanding Strike Price
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Upcoming IPO Stock Lockup Period, Explained
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- How to Effectively Use the MarketBeat Ratings Screener
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.